View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 1, 2021

ObvioHealth to launch clinical trial of Anatara’s GaRP in Australia

The trial will use in-home data collection methods which will reduce or eliminate the need for follow-up visits to clinics.

ObvioHealth is to launch a decentralised clinical trial to evaluate Anatara Lifesciences’ Gastrointestinal ReProgramming (GaRP) product in Australia.

The trial will evaluate the safety and efficacy of the product for participants with irritable bowel syndrome–diarrhoea (IBS-D) subtype.

GaRP is a microbiome-targeted multi-component complementary medicine, which aims to address the underlying factors related to chronic gastrointestinal conditions that include irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

The randomised, double-blind, placebo-controlled trial will use a combination of in-home data collection methods, which will reduce or eliminate the need for follow-up visits to clinics.

Patients will use ObvioHealth’s easy-to-use smartphone application to report the severity of IBS-D symptoms, as well as the anticipated relief, quality of life, treatment adherence and changes in health status.

The ObvioHealth platform will gather all the data from the application and allow the research team to monitor the changes in real-time and quickly detect possible adverse events, as well as issues with protocol adherence.

Anatara Lifesciences CEO Steve Lydeamore said: “IBS impacts around one in five Australians at some point in their life with no current definitive cure.

“It is anticipated that GaRP’s mechanism of action will relieve symptoms of IBS-D by reducing inflammation and assisting repair of the gut lining, positively influencing the homeostasis and metabolites of the microbiome.”

During the clinical trial, a study nurse will pay in-home visits to measure vitals and collect samples.

The use of ObvioHealth’s technology helps in virtual data collection and supports enrolment for the study anywhere in Australia and diversifying the study population.

In March, ObvioHealth announced the launch of a Phase II/III study of RedHill Biopharma’s RHB-107 (upamostat) in the US for the treatment of Covid-19.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU